We will present new Phase 2 data for VTX958, our allosteric TYK2 inhibitor for Crohn’s disease, this week at ECCO 2025. The results highlight a strong dose-dependent endoscopic response and reductions in key inflammatory markers, supporting the potential of VTX958 as a safe and effective an oral treatment option. Dr. Silvio Danese, Professor of Gastroenterology at Vita-Salute San Raffaele University, commented: "These Phase 2 data suggest that VTX958 has potential for disease-modifying benefit in Crohn’s disease, including strong effects on endoscopic response, an outcome measure increasingly preferred as a primary endpoint in Phase 2 trials based on its stringency and objectivity." Read more: https://bit.ly/3EJ9yMY
关于我们
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
- 网站
-
https://ventxybio.com/
Ventyx Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego，California
- 类型
- 上市公司
地点
-
主要
获取路线
12790 El Camino Real
US，California，San Diego
Ventyx Biosciences员工
动态
-
#ICYMI: Ventyx Founder & CEO Raju Mohan and CMO Mark Forman joined Jeff Jones at the Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference for a deep dive into the development strategy for our NLRP3 inhibitors VTX2735 and VTX3232, including three Phase 2 data readouts expected this year. Listen to the full conversation here: https://lnkd.in/exGiwz2C
-
-
We are looking forward to participating in the upcoming Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference! We will be highlighting recent developments on our innovative oral therapies for #Autoimmune, #Inflammatory, and #NeurodegenerativeDiseases in a virtual fireside chat. Date: February 12, 2024 Location: Virtual Time: 2:40-3:10PM ET Register here: https://bit.ly/4aNC2kA
-
-
At Ventyx Biosciences, we're committed to developing innovative oral therapies for #Autoimmune, #Inflammatory, and #NeurodegenerativeDiseases. Our 2025 pipeline strategy highlights key progress, including three anticipated data readouts in 2025 for our NLRP3 inhibitors, VTX2735 and VTX3232. Read more: https://lnkd.in/ej-Epx8q
-